Signet Therapeutics Highlights SIGX1094 Progress on World Gastric Health Day

SIGNET is committed to biopharmaceutical innovation, bringing more hope of cure to patients. The companyThe core pipeline SIGX1094 is the world's first targeted drug for diffuse gastric cancer and the first FAK/SRC dual-target inhibitor to enter the clinical stage globally. It is currently undergoing Phase I clinical trials at the Peking University Cancer Hospital, demonstrating good safety and preliminary efficacy in the dose-escalation trial of Phase I. SIGX1094 has also received Orphan Drug Designation and Fast Track Designation from the U.S. FDA.

April 9th is "International Stomach Health Day." Using technology to target stomach health, SIGNET remains committed to the journey.

SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a National High-tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since secured nearly 220 million yuan in financing and project funding. Signet Therapeutics currently has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China’s NMPA, as well as Orphan Drug Designation and Fast Track Designation from the U.S. FDA. Phase I clinical trials are currently underway at Peking University Cancer Hospital.

Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Full of Hope, Investigating Things to Gain Knowledge." The company leverages organoid disease models that closely resemble patients' genomic characteristics for critical applications in drug efficacy evaluation and new target discovery. Combined with AI-powered screening, synthesis, and optimization of small molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has approximately 1,500 square meters of R&D space and 500 square meters of experimental animal housing. Signet Therapeutics' organoid platform not only supports its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the creation of more innovative drugs.